Trial Profile
Randomized Phase II Study of First-Line Treatment With Gemcitabine vs. Erlotinib vs. Gemcitabine and Erlotinib in Elderly Patients With Stage IIIB/IV Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2017
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Jun 2011 Status changed from recruiting to completed; results have been published in full.
- 08 Jun 2010 Preliminary results presented at the 46th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jun 2010 A total of 144 patients of the planned 147 have been enrolled, according to an ASCO 2010 abstract.